INTERNATIONAL
ORGAN TRANSPLANT FORUM

Honoring
THOMAS E. STARZL

September 8-11, 1987
Pittsburgh, Pennsylvania

EDITORS

Henry T. Bahnson
Pittsburgh, Pennsylvania

Carl G. Groth
Stockholm, Sweden

Felix T. Rapaport
Stony Brook, New York

GRUNE & STRATTON
Harcourt Brace Jovanovich, Inc.
INTERNATIONAL
TRANSPLANT FORUM

AWARD WINNING PRESENTATIONS

First Prize

Studies on FK506 in Experimental Organ Transplantation
T. Ochiai, K. Sakamoto, M. Nagata, K. Nakajima, T. Goto,
S. Hori, T. Kenmochi, T. Nakagouri, T. Asano, and K. Isono
Department of Surgery, School of Medicine, Chiba University, Japan

Second Prize

Indication, Technique, and Results of Liver Graft Volume Reduction Before Orthotopic Transplantation in Children
M. Salizzoni, T. Yandza, P.J. Kestens, B. de Hemptinne, and J.B. Otte
Cliniques St-Luc, Brussels
CONTENTS

INTRODUCTION

Foreword ........................................... H.T. Bahnson and C.G. Groth 1
Thomas E. Starzl ........................................... C.G. Groth 5
Address.......................................................... C.E. Koop 6
Remarks ....................................................... B. Osborne 9
In a Small Iowa Town ....................................... T.E. Starzl 12

IMMUNOBIOLOGY AND IMMUNOSUPPRESSION

HISTOCOMPATIBILITY

The Second Histocompatibility Locus in Humans ....................... P.I. Terasaki,
D. Chia, and M.R. Mickey 21
Living Related Kidneys Continue to Provide Superior Results Over Cadaveric Kidneys
in the Cyclosporine Era ............ J.P. Roberts, D.S. Fryd, N.L. Ascher, R. Migliori,
W.D. Payne, D.D. Dunn, D.E.R. Sutherland, R.L. Simmons, and J.S. Najarian 26
HLA Class I and II Antigen Matching From a Single Large Kidney Transplant
Early Graft Loss .......................................... M.R. Mickey, Y. Cho, and P.I. Terasaki 31

(Continued)
CONTENTS
(continued)

Do Shared HLA Antigens Between Present and Past Donors Adversely Affect Graft Survival in Recipients With a Past Positive Donor Crossmatch?
D. Senitzer, A.J. Matas, V.A. Tellis, F.J. Veith, and R. Soberman 34


Benefit of Histocompatibility in Cyclosporine-Treated Recipients of First Cadaveric Renal Transplants and Implications for Kidney Sharing..................H. Takiff, J. Cicciarelli, L. Yin, and P.I. Terasaki 39

Long-Term Results in Recipients of Mismatched Related and Unrelated Living Kidneys in the Cyclosporine Age.............R. Cortesini, P. Berloco, A. Famulari, E. Renna-Molajoni, M. Iappelli, M. Rossi, M. Caricato, R. Pretagostini, A. Bachetoni, and D. Alfani 41


Natural Anti-IgG Antibodies to Autologous and Heterologous Species IgG L. Fuller, M. Carreno, V. Esquenazi, D. Roth, and J. Miller 45


Long-Term Τ Cell Lines Derived From Canine Rejecting Renal Allografts Preferentially Recognize Kidney Associated Antigens ..................V. Esquenazi, N. Iglesias, L. Fuller, D. Roth, M. Milgrom, L. Olson, and J. Miller 49

Cloned Helper Τ Cells Display Parallel Specificities by In Vitro Proliferation and In Vivo Generation of Delayed Type Hypersensitivity ..................G. Bumgardner, D.R. Cahill, S.M. Clemmings, and N.L. Ascher 52

Adherence of Allogeneically Primed Lymphocytes to Human Arterial Endothelial Cell Monolayers .....................Y.L. Colson, B.H. Markus, A. Zeevi, and R.J. Duquesnoy 54

Anti-HLA-D Antibodies (α-HLA-D) in Renal Allograft Recipients M. Nowaczyk, L. Paczek, J. Wyzgat, M. Morzycka-Michalik, and A. Gorski 57

Leukocyte Expression of Class II Antigens in Renal Allograft Recipients A. Gorski, M. Nowaczyk, L. Paczek, J. Wyzgat, and R. Gellert 59

An Immunologic Method of Islet Cell Purification Using Cytotoxic Anti-Acinar Cell Monoclonal Antibodies ......................P. Soon-Shiong, R. Heintz, and P. Terasaki 61

Liver-Specific Allo- and Autoantibodies in the Antibody Response of Allografted Pigs D. Eisenmann, M. Smetak, and H. Bockhorn 64

(Continued)
Expression of Monomorphic and Polymorphic Major Histocompatibility Complex Determinants in Human Heart Grafts .................................. G. Steinhoff, K. Wonigeit, H.J. Schäfers, and A. Haverich 67

Tissue Expression of Major Histocompatibility Complex (HLA) Antigens in Cardiac Allograft Recipients ......................... T. Zerbe, L. White, A. Zeevi, R. Hardesty, B. Griffith, and R. Duquesnoy 72

Role of Major Histocompatibility Complex (HLA) Matching in Cardiac Allograft Rejection................................. T. Zerbe, V. Arena, R. Kormos, Y. Colson, B. Griffith, and R. Hardesty 74

Shedding and Turnover of Class I Transplantation Antigens in the Rat H.W. Harris, H.W. Kunz, and T.J. Gill, III 76

Elimination of Ia⁺ Passenger Cells in Rat Hearts ................. H.M. Gebel, Y. Umeki, and S.G. Economou 78

CROSSMATCHING AND IMMUNOLOGICAL MONITORING


An Automated Procedure for Performing Large Numbers of Pretransplant Crossmatch Tests .................................. K.E. Lysz, J.C. Rosenberg, M.P. Kaplan, T.C. Williams, and D.R. Bethell 86


Experience With Donor-specific Cytotoxic T Cell Monitoring for Kidney Transplant Rejection and Strategy for Improvement ........... T. Kovithavongs, V. Yacyshyn, K. Rohachuk, and J.B. Dossetor 95

Early Detection of Impending and Incipient Allograft Rejection ................. J.E. Fuhr and M.H. Goldman 98

(Continued)

Early Postoperative Antibody Monitoring in Renal Allotransplantation Using the Donor Specific Complement-Dependent Lymphotoxicity ......................... X. Tang, Y. Yang, K. Li, and W. Shen 105


Immunologic Analysis of Cellular Infiltrates During Human Renal Allograft Dysfunction .... W.C. Waltzer, F. Miller, A. Arnold, D. Anaise, and F.T. Rapaport 111

SPECIFIC ALLOGENEIC UNRESPONSIVENESS

Synergistic Immunosuppressive Strategies for the Induction of Allogeneic Unresponsiveness in the Adult Host ......................... F.T. Rapaport 114

Total Lymphoid Irradiation in Transplantation ............................... J.A. Myburgh 118


In Vitro Immune Responsiveness in Rats Transfused with Ultraviolet Irradiated Donor-Specific Blood ........................................... S.F. Oluwole, J. Chabot, P. Pepino, K. Reemtsma, and M.A. Hardy 131


Thy-1+ Cells Required for Tolerance Induction to Skin Allografts by Semiallogeneic F1 Donor Spleen Cells ............................................ G.E. Pierce and L.M. Watts 137

The Necessity of Both Allogeneic Antigens and Stem Cells For Cyclophosphamide-Induced Skin Allograft Tolerance in Mice H. Mayumi and R.A. Good 139

Analysis of Tolerance Induced in Dogs With Renal Allografts After Alternate-Day Therapy With Cyclosporine and Azathioprine .............................. H.J.S. Davies, D.St.J. Collier, S. Thiru, and R. Calne 142


(Continued)
CONTENTS

IMMUNOSUPPRESSION

Cyclosporine

Immunosuppression: Building on Sandimmune (Cyclosporine) .................. J.F. Borel 149

Experimental Study About the Influence of Liver Dysfunction Upon Cyclosporine Pharmacokinetics .................................................. S. Takaya, S. Iwatsuki, T.E. Starzl, I. Zagloul, T. Noguchi, Y. Ohmori, G.J. Burckart, R.J. Ptachcinski, and R. Venkataramanan 154

Extended Cardiac Allograft Survival in Recipients Treated Only With Pretransplant Cyclosporine .............. H.M. Gebel, Y. Umeki, C. MacLeod, and S.G. Economou 157


Cholestasis After Cyclosporine A and Glucose Administration: Beneficial Effect of Canrenoate (Soldactone) .......... Ø. Mathisen, E. Omland, and A. Flatmark 160

Effect of Chronic Therapy on Absorption and Disposition of Cyclosporine K. Habucky, R. Venkataramanan, R.J. Ptachcinski, G.J. Burckart, S. Todo, and T.E. Starzl 162


(Continued)
CONTENTS (continued)

Effect of a Stable Analogue of Prostacyclin on Cyclosporine A-Induced Nephrotoxicity: Morphological Qualitative and Quantitative Studies
M. Kobayashi, S. Takaya, and H. Koie 183

Effect of Cyclosporine on Prostacyclin Production by Human Endothelial Cells
W.V. Sharp, T.R. Pippert, B.J. Igel, and S.P. Schmidt 187

Cyclosporine Metabolites in Human Bile: Recovery and Immunologic Activity


The Effect of Carrier Vehicle on Cyclosporine-Induced Unresponsiveness to Rat Cardiac Allografts .........................K.L. Brayman, J.F. Markmann, A. Roza, C.F. Barker, L. Shaw, and A. Naji 197

The Effects of Antilymphocyte Serum and Cyclosporine on Orthotopic Small Bowel Allografts in the Rat ....................T. Diflo, D. Shaffer, T. Maki, and A.P. Monaco 200


FK506

Studies on FK506 in Experimental Organ Transplantation

Effect of FK506 in Experimental Organ Transplantation

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs
A. Zeevi, R. Duquesnoy, G. Eiras, H. Rabinowich, S. Todo, L. Makowka, and T.E. Starzl 220

The Effect of FK506 on Segmental Pancreas Allografts in Mongrel Dogs

FK506 in Experimental Renal Allografts in Dogs and Primates..........D.St.J. Collier, R. Calne, S. Thiru, P.J. Friend, S. Lim, D.J.G. White, H. Kohno, and J. Levickis 226

(Continued)
Deoxyspergualin

15-Deoxyspergualin as an Immunosuppressive Agent in Dogs

Effect of 15-Deoxyspergualin on Experimental Organ Transplantation


15-Deoxyspergualin in Experimental Dog Renal Allografts D.St.J. Collier, R. Calne, S. Thiru, H. Kohno, and J. Levickis 240

Monoclonal Antibodies

Prophylactic Use of OKT3 in Renal Transplantation: Part of a Prospective Randomized Multicenter Trial J.R. Ackermann, W.M. LeFor, L. Kahana, S. Weinstein, and D.L. Shires 242


Indications and Outcome of OKT3 Therapy After Liver, Pancreas, and Renal Transplantation F.L. Delmonico, H. Auchincloss, Jr, H. Yang, P.S. Russell, and A.B. Cosimi 249


The Use of OKT3 Rescue Therapy After Orthotopic Liver Transplantation—The University of Nebraska Medical Center Experience R.P. Wood, B.W. Shaw, Jr, and L. Williams 254

Sustained Periods Without Rejection After Treatment of Cardiac Allograft Recipients with OKT3 J.B. Klein, K.R. McLeish, C.M. Bunke, B. Chang, J.A. Brohm, and L.A. Gray, Jr 260

Mechanism of Anti-Helper Cell Monoclonal Antibody Immunosuppression W.R. Maley, L.W. Clow, and J.F. Burdick 263

(Continued)
CONTENTS
(continued)

Monoclonal Antibodies That Recognize Activated Human Lymphocytes—
Experimental and Clinical Studies ...................... P.J. Friend, H. Tighe, H. Waldmann,
S. Lim, D.St.J. Collier, D. Campbell, S. Thiru, and R. Calne 265 ♦

Recognition of Class II and Non-Major Histocompatibility Complex Allodeterminants
by T Cells When Using Human Monocyte Hybridomas.. A. Shaked and L. Mayer 267 ♦

Effect of L3T4 and Lyt-2 Monoclonal Antibodies on Pancreatic Islet Allograft
Survival............... H. Yamamoto, M. Monden, T. Ichikawa, M. Gotoh, N. Kubota,
M. Kawai, J. Okamura, T. Mori, E. Nakayama, and A. Uenaka 269 ♦

Anti-Interleukin 2 Receptor Monoclonal Antibody Therapy in Rat Recipients of
Cardiac Allografts: The Role of Antibody Isotype
J.W. Kupiec-Weglinski, R. Di Stefano, K.G. Stunkel, R. Grutzmann, P. Theisen,
D. Araneda, N.L. Tilney, and T. Diamantstein 272 ♦

Immunosuppression and Neoplasia

Cancers After Cyclosporine Therapy ......................................................... I. Penn 276

Clonal Characteristics of Posttransplant Lymphoproliferative Disorders
M.A. Nalesnik, J. Locker, R. Jaffe, A.J. Demetris, K. Hartle, J.A. Burnham,
L. Makowka, and T.E. Starzl 280

Kaposi’s Sarcoma in Organ Transplant Recipients: Report of Four Cases
J. Homatas, J. Karavasilis, S. Kyriakidis, K. Megalokonomos, S. Kontostolis,
G. Zavos, T. Vlassis, and A. Kostakis 284

IMMUNOMODULATION

Blood Transfusions

A Randomized Comparison of Preoperative and Intraoperative Transfusions in
Recipients of First Cadaveric Renal Allografts......................... L.G. Hunsicker,
B.A. Schanbacher, N.E. Goeken, and R.J. Corry 286

An Alternative, Effective Pretransplant Transfusion Method: Small-Aliquot, Repeated
Transfusions From the Same Third-Party, HLA-Defined Blood Donor
L. Burrows, H. Schanzer, C. Miller, R. Feingold, and M. Fotino 289

Blood Transfusions Affect the Incidence of Rejection but Not Graft Survival in
HLA-Identical Renal Transplants
R.R.M. Gifford, A.D. Bannett, S.M. Greenstein, S. Simonian, C.F. Barker,
A. Naji, L.J. Perloff, R.A. Carabasi, B.E. Jarrell, and M.J. Moritz 292

(Continued)
CONTENTS

(continued)


The Effect of Azathioprine on Sensitization Due to Donor-Specific Blood Transfusion M. Haberal, S. Sert, N. Aybasti, H. Gulay, O. Gokce, O. Bulut, and N. Bilgin 300

UV Radiation

Suppression of Graft Rejection and the Induction of Graft-v-Host Disease by Exposure to UV Radiation .......................................................... S.E. Ullrich 302

A New Method of Immunosuppression by Selective Destruction of Cytotoxic T Cells With Photodynamic Effect............ M. Sakurada, S. Satomi, Y. Taguchi, and S. Mori 305

Other Approaches

Thymosin Enhances the Immunosuppressive Effect of Cyclophosphamide on Immunoglobulin Synthesis in Mice .............. L. Paczek, Z. Gaciong, A. Górski, Z. Łagodziński, and T. Glapiński 309

Pretreatment of Vascularized Organ Allografts With a Daunomycin Antibody Conjugate to Alter Allograft Immunogenicity ............ R. Pollak, C.W. Chang, M.F. Lee, J.M. Blanchard, V.A. Lazda, and M.F. Mozes 311

Prolongation of Rabbit Skin Allograft Survival With Immunosuppression and Specific Antagonist of Platelet-Activating Factor ........... J.C. Muiño, J.P. Ruggieri, A. Alè, and H.A. Cejas 313

Effect of Restricting Prostaglandin E Availability on the Host-v-Graft Response in Mice.......................................................... J. Shelby, M.M. Ives, and T.R. Freeman 316

Immunosuppressive Treatment of Multiple Sclerosis: 24 Years’ Experience With a Spinoff From the Transplant Surgeons................................................. J.A. Rosen 318

Effects of Host Immunosuppression on Grafted Tissue ......................... H.D. Edington, S.W. Caughman, and P.H. Sugarbaker 320

Regulation of Antigen Expression on the Placenta: A Unique Type of Immunosuppression....................... A. Kanbour, H-N. Ho, D. Misra, T. Macpherson, H.W. Kunz, and T.J. Gill, III 323

XENOTRANSPLANTATION

Xenotransplantation: A Quarter Century of Experience ....................... K. Reemtsma 325

(Continued)
CONTENTS
(continued)

Macaque-to-Baboon Cardiac Transplantation: Model of Choice for Xenotransplantation in Humans

An Important Role of the Spleen in Rejection of Hamster-to-Rat Xenografts

TRANSPANTATION BIOLOGY

Growth of Craniofacial and Forelimb Allotransplants in Young Rabbits
D.W. Furnas, J. Randzio, H. Kniha, G.M. Fudem, H.G. Cruz, and M.E. Gold 332

Preservation of Nerve Function in an Allogenic Hand Transplant Model in Primates
K. Narayanan, W.M. Swartz, B. Stark, A. Moller, and B.L. Munger 335

KIDNEY TRANSPLANTATION

THE PAST, PRESENT, AND FUTURE

Renal Transplantation Before Starzl
J.E. Murray 339

Renal Transplantation—The Starzl Influence
O. Salvatierra, Jr 343

Multivariate Analysis of Risk Factors Leading to Kidney Graft Loss in Cyclosporine-Treated Patients
N.R. StC. Sinclair, C.R. Stiller, J.R. Jeffery, and P.A. Keown for the Canadian MultiCentre Transplant Study Group 350

Living Donor Kidney Transplantation
M. Haberal, S. Sert, N. Aybasti, H. Gulay, O. Gokce, G. Arslan, M. Karamehmetoglu, and N. Bilgin 353

Results of Cadaver Renal Transplantation Using “In-House” Donors and Recipients
R.M. Dickerman, P. Vergne-Marini, G. Trevino, J.W. Langley, K. Brinker, and M.G. White 356

The Optimal Use of Pediatric Donors for Renal Transplantation
G. Trevino, R.M. Dickerman, J.T. Coggins, W. Greene, W. Freeborn, and P. Vergne-Marini 359

Early Kidney Transplant Function Can Be Used to Predict 1-Year Graft Survival
J. Cicciarelli and P. Terasaki 363

Widening the Indications for Renal Transplantation: Cadaver Kidney Transplants in Obese Patients
F.K. Merkel, J. Yeung, S. Humphreys, T. Sehey, P. Crawford, and J. Ball 365

Renal Replacement Therapy in Elderly Patients
D. Albrechtsen, P. Fauchald, T. Leiestad, T. Talseth, and A. Flatmark 367

Intraperitoneal Placement of Renal Transplants
F.K. Merkel and T.A.S. Matalon 370

(Continued)
CONTENTS
(continued)
The Effect of Referring Dialysis Center on Cadaver Kidney Transplant Outcome
A.J. Matas, V.A. Tellis, T. Quinn, D. Glicklich, R. Soberman, and F.J. Veith 375

Sequential Cardiac Evaluation of the Kidney Transplant Candidate .......... M. Houff,
J. Haimes, P. DeLone, S. Goldstein, and J.A. Light 377

Quality of Life and Rehabilitation Differences Among Alternate End-Stage Renal
Disease Therapies........................................... R.G. Simmons and L. Abress 379

The Effect of an Exercise Training Program in Renal Transplant Recipients
G.L.G. Kempeneers, K.H. Myburgh, T. Wiggins, B. Adams, R. Van Zyl-Smit,
and T.D. Noakes 381

Kidney Donation: Attitude Findings .................................. A. Spital and M. Spital 383

TIMY—A Center-Oriented Transplant Information Management System
B.H. Markus, S. Mitchell, R.D. Gordon, B. Gillquist, A.G. Tzakis,
and T.E. Starzl 385

The Development and Implementation of a University-Based, Graduate-Level Course
in Organ Procurement and Transplantation....... B. Sammons and M.I. Applegate 391

VARIATIONS IN IMMUNOSUPPRESSIVE THERAPY

The Intake of Initially High Doses of Cyclosporine A in Cadaveric Kidney
Transplantation Is Not Justified. Results of a Prospective Study .......... W. Niebel,
K.H. Albrecht, K. Metz, H-D. Jakubowski, R. Windeck, and F.W. Eigler 394

Improved Results in Cadaveric Renal Transplantation for Black Recipients

Two Immunosuppressive Drug Regimens After Renal Transplantation: Low Dosage of
Cyclosporine Adjusted on the Basis of High-Performance Liquid
Chromatography Whole Blood Levels and Prednisone ....................... K. Uchida,
A. Orihara, N. Yamada, Y. Tominaga, M. Kawai, Y. Tanaka, K. Morozumi,
S. Hayashi, M. Satake, N. Taira, T. Haba, H. Kato, H. Asano,
T. Kano, and H. Takagi 401

A Clinical Study of Renal Transplant Patients Receiving Triple-Drug
Therapy—Cyclosporine A, Mizoribine, and Prednisolone ............... F. Marumo,
M. Okubo, K. Yokota, H. Uchida, K. Kumano, T. Endo,
K. Watanabe, and N. Kashiwagi 406

Quadruple-Drug Induction Therapy in Highly Sensitized Patients .......... W-D. Illner,
S. Schleibner, D. Abendroth, and W. Land 410

 Superior Cadaver Renal Transplantation Survival and Increased Cost-Effectiveness
Using Individualized Quadruple Immunosuppression.................... F. Thomas,
P. Cunningham, C. Sash, U. Gross, and J. Thomas 412

(Continued)
CONTENTS


Regression of Recurrent Membranoproliferative Glomerulonephritis Type II in a Transplanted Kidney After Plasmapheresis Therapy ..............O.R. Oberkircher, M. Enama, J.C. West, P. Campbell, and J. Moran 418


COMPLICATIONS


Experimental Cardiac Transplantation and Chronic Chagas' Disease in Dogs F. Boullon, A. Sinagra, A. Riarte, M. Lauricella, J. Barra, M. Besanson, C. Lejour, O. Lopez Blanco, R. Favaloro, and E.L. Segura 432

Metabolic Problems in Renal Transplant Patients. Persistent Hyperparathyroidism and Hypophosphatemia: Effects of Intravenous Calcium Infusion R.C. Pabico, B.A. McKenna, and the Renal Transplant Team 438

Neurological Complications After Kidney Transplantation L.A. Morales-Otero, Z.A. González, and E.A. Santiago-Delpín 443

Early Colonic Bleeding and Kidney Transplantation..........B. Siegal and A. Horowitz 446


THE HYPERIMMUNIZED RECIPIENT

Hyperacute Rejection of the Kidney in Patients With a Negative Crossmatch B. Banner, L. Makowka, J. Demetris, A. Tzakis, M. Griffin, and T.E. Starzl 453

A New Approach to Transplantation of Sensitized and Regraft Patients: Use of Trauma Donors ..................................................J.M. Cecka and P.I. Terasaki 460

(Continued)
INFECTION

Factors in an Outbreak of *Pneumocystis carinii* in a Transplant Unit
E.A. Santiago-Delpin, E. Mora, Z.A. González, L.A. Morales-Otero,
and R. Bermúdez 462

Are the Risks of Viral Infections Increased in Kidney Transplant Patients Receiving
Triple-Drug Therapy.................... B. Greger, W.D. Schareck, M. Büsing, J. Mellert,
G.H. Müller, U.T. Hopt, and H. Bockhorn 466

Four-Year Experience With Exclusive Use of Cytomegalovirus Antibody
(CMV-Ab)–Negative Donors for CMV-Ab–Negative Kidney Recipients
J.R. Ackermann, W.M. LeFor, S. Weinstein, L. Kahana, D.L. Shires, G. Tardif,
and J. Baxter 469

LIVER TRANSPLANTATION

CLINICAL STUDIES

Liver Transplantation: The Recent Cambridge/King’s College Hospital Experience
R.Y. Calne 475

Is There a Place for Liver Grafting for Malignancy? ...................... R. Pichlmayr 478

The Pathology of Rejection in Human Liver Allografts ..................... K.A. Porter 483

Liver Transplantation: The Paul Brousse Experience .................... H. Bismuth 486

Liver Transplantation: The Promise of the Past and the Future
D.H. Van Thiel, V. Dindzans, R.R. Schade, J.S. Gavaler, and R.E. Tarter 490

Regulation of Liver Size and Regeneration: Importance in Liver Transplantation
A. Francavilla, P. Ove, L. Polimeno, M. Coetzee, L. Makowka, M. Barone,
D.H. Van Thiel, and T.E. Starzl 494

Experience in 1,000 Liver Transplants Under Cyclosporine-Steroid Therapy: A
Survival Report .................................. S. Iwatsuki, T.E. Starzl, S. Todo, R.D. Gordon,
C.O. Esquivel, A.G. Tzakis, L. Makowka, J.W. Marsh, B. Koneru,
A. Stieber, G. Klintmalm, and B. Husberg 498

Decreased Mortality Associated With Orthotopic Liver Transplantation
R.M. Goldstein, L.M. Olson, G.B.G. Klintmalm, B.S. Husberg, J.R. Nery,
T.A. Gonwa, J.S. Roden, and D.E. Polter 505

The Technique of Liver Size Reduction in Orthotopic Liver Transplantation
B. de Hemptinne, M. Salizzoni, K.C. Tan, and J.B. Otte 508

(Continued)
CONTENTS

The Activity of the Liver Transplant Center of Milan, Italy...L.R. Fassati,
B. Gridelli, G. Rossi, M. Colledan, G. Ferla, M. Doglia, P. Reggiani,
G. Pezzuoli, and D. Galmarini 512

Experience With Pediatric Liver Transplantation in Barcelona, Spain
V. Martínez-Ibañez, C. Margarit, G. Barat, J. Iglesias, P. Dominguez,
R. Tormo, D. Infante, and J. Boix-Ochoa 516

Experimental Auxiliary Liver Transplantation: Lack of Evidence for Functional
Competition.........................O.T. Terpstra, A. Dekker, and C.B. Reuvers 519

Can a Liver Graft From the Same Donor Protect a Kidney From Rejection?
R. Margreiter, R. Kornberger, J. Koller, E. Steiner, M. Spielberger, F. Aigner,
T. Schmid, and W. Vogel 522

Quadruple Immunosuppressive Therapy for Liver Transplantation
M. Kalayoglu, R.J. Stratta, R.M. Hoffmann, H.W. Sollinger, and F.O. Belzer 524

Blood Use in Transplantation: Liver, Heart, Artificial Heart, and Heart-Lung
J.H. Lewis, F.A. Bontempo, F.W. Cornell, J.A. Spero, M.V. Ragni, J.E. Kiss,
and E.O. Rice 530

The Relation of Preoperative Coagulation Function and Diagnosis to Blood Usage in
Pediatric Liver Transplantation.............................L.M. Borland and M. Roule 533

A New Method for Extracorporeal Bypass in Orthotopic Liver Transplantation Using
a Splenic Vein Cannulation With Metal Cannulas..........H. Karlsson, C. Adams,
B. Foil, S.N. Kim, and F.T. Thomas 536

Stable Hemodynamics During Heterotopic Auxiliary Partial Liver Transplantation for
End-Stage Liver Cirrhosis..............T.H.N. Groenland, L. Visser, O.T. Terpstra,
J.L. Terpstra, C.B. Reuvers, D. Baumgartner, and S.W. Schalm 538

Biliary Tract Reconstruction Using External Cholecystostomy Without Stenting in
Liver Transplantation ...............................W.J. Wall, D.R. Grant, and J.H. Duff 541

Biliary Tract Reconstruction in Orthotopic Liver Transplantation.........R.R. Hollins,
R.P. Wood, and B.W. Shaw, Jr 543

Experimental and Clinical Reduced-Size Orthotopic Liver Transplantation: A New
Method for Securing Hemostasis.........................C. Margarit, V. Martínez-Ibañez,
J. Lloret, R. Isnard, H. Ventura and J. Boix-Ochoa 546

Orthotopic Liver Transplantation of Liver Grafts Previously Resected In Situ
I.R. Marino, C.O. Esquivel, G. De Luca, E. Santini, S. Celli, M.M. Napolitano,
C. DiPietro, A. Frena, P. Bevilacqua, C. Cavicchioni, V. Mazzaferrro,
B.H. Markus, G. De Francisci, P.G. Falappa, and L. Perrelli 548

Total Hepatectomy as Temporary Approach to Acute Hepatic or Primary Graft
Failure ................B. Ringe, R. Pichlmayr, N. Lübke, A. Bornscheuer, and E. Kuse 552

(Continued)
CONTENTS
(continued)

Chronic Therapeutic Plasma Exchange for Poor-Prognosis Primary Biliary Cirrhosis Patients Awaiting Liver Transplantation..........................J.E. Louie, E.P. Ambinder, M. Miranda, M. Greenberg, F. Klion, and F. Schaffner 558

Liver Transplantation in Patients With Preexisting Acute and Chronic Renal Failure
T.A. Gonwa, G.B. Klintmalm, B.S. Husberg, L. Olson, J. Nery, and J. Roden 561


Orthotopic Liver Transplantation as a Successful Treatment for Familial Hypercholesterolemia...............J.A. Cienfuegos, V. Turrión, F. Pardo, J. Ardaiz, N.P. Mora, P. Escartin, C. Barrios, V. Cuervas-Mons, and A. Garrido 570


When Should a Patient With Primary Biliary Cirrhosis Receive a Transplant? F.M. Klion, F. Schaffner, and T. Fabry 577


Continuous Nutritional Therapy in Five Pediatric Patients With Extrahepatic Biliary Atresia in Hepatic Transplant Program .................. M. Marcellini, M. Palumbo, M. Gambarara, M. Castro, M. Rivosecchi, and F. Bergami 588


Assessment of the Information Needs of Mothers of Children After Liver Transplantation ........................................N.K. Weichler 598

(Continued)
CONTENTS

COMPICATIONS

Intraoperative Mortality During Liver Transplantation .............. Y. Kang, S. Aggarwal, and J.A. Freeman 600

Human Orthotopic Liver Transplantation: Surgical Aspects in 393 Consecutive Grafts
J.R. Lerut, R.D. Gordon, S. Iwatsuki, and T.E. Starzl 603


Treatment of Hepatic Artery Thrombosis After Liver Transplantation With Immediate Vascular Reconstruction: A Report of Three Cases
G.B. Klintmalm, L.M. Olson, J.R. Nery, B.S. Husberg, and A.W. Paulsen 610

An Analysis of the Causes of Death After Pediatric Liver Transplantation
D. Kahn, C.O. Esquivel, M. Madrigal-Torres, S. Todo, E. Yunis, S. Iwatsuki, and T.E. Starzl 613


The Use of Nonheparinized Hemodialysis After Orthotopic Liver Transplantation—The University of Nebraska Medical Center Experience
M.V. Wilson, T.F. Knight, B.W. Shaw, Jr, and R.P. Wood 634

(Continued)
CONTENTS
(continued)


Chronic Renal Dysfunction and Hypertension After Hepatic Transplantation in Adults Treated With Cyclosporine A ......................... B. Ringe, W.O. Bechstein, H. Bunzendhal, K. Wonigeit, U. Frei, and R. Pichlmayr 639

Upper Airway Obstruction and Lymphoproliferative Disease in Children After Liver Transplantation .............................................. N. Sculerati and S.E. Stool 642


Fungal Infections After Liver Transplantation .......................................................... S. Kusne, J.S. Dummer, N. Singh, L. Makowka, C. Esquivel, T.E. Starzl, and M. Ho 650

Successful Treatment of Cytomegalovirus Disease With 9-(1,3-Dihydroxy-2-Propoxymethyl Guanine) ........ B. de Hemptinne, M.E. Lamy, M. Salizzoni, C. Cornu, J. Mostin, J. Fevery, V. De Groote, and J.B. Otte 652

Cutaneous Cytomegalovirus in a Liver Transplant Patient ....................... R. Elenitsas and B.A. Cohen 656


Impact of OKT3 Therapy on Cytomegalovirus and Herpes Simplex Virus Infections After Liver Transplantation ................. N. Singh, J.S. Dummer, S. Kusne, L. Makowka, T.E. Starzl, and M. Ho 661

DIAGNOSIS OF REJECTION


Can Serum Liver Function Tests Differentiate Rejection From Other Causes of Liver Dysfunction After Hepatic Transplantation? ........ H.N. Sankary, J.W. Williams, and P.F. Foster 669

Monitoring of Serum Neopterin Levels After Liver Transplantation ...... K.J. Oldhafer, O. Schaefer, K. Wonigeit, B. Ringe, and R. Pichlmayr 671

(Continued)
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study of Eosinophilia and Hepatic Dysfunction as a Predictor of Rejection in Human Liver Transplantation</td>
<td>P.F. Foster, H. Sankary, and J.W. Williams</td>
<td>676</td>
</tr>
<tr>
<td>Percutaneous Transhepatic Cholangiography Rather Than Ultrasound as a Screening Test for Postoperative Biliary Complications in Liver Transplant Patients</td>
<td>A.B. Zajko, G. Zemel, M.L. Skolnick, K.M. Bron, W.L. Campbell, S. Iwatsuki, and T.E. Starzl</td>
<td>678</td>
</tr>
<tr>
<td>Liver Transplant Aspiration Cytology as a Clinical Tool for Diagnosing Allograft Rejection</td>
<td>I. Fehrman, C.L. Greene, W. Tillery, G. Klintmalm, and B. Husberg</td>
<td>685</td>
</tr>
<tr>
<td>Liver Transplant Aspiration Cytology Is a Useful Tool for Identifying and Monitoring Allograft Rejection</td>
<td>C.L. Greene, I. Fehrman, G.W. Tillery, B.S. Husberg, and G.B. Klintmalm</td>
<td>687</td>
</tr>
<tr>
<td>The Impact of Fine-Needle Aspiration Biopsy for Monitoring Liver Transplants: Cytological and Hepatocyte MHC-DR Expression Patterns During Rejection</td>
<td>A. Zannier, J.L. Faure, P. Champetier, P. Takvorian, M. Mutin, and J. Neidecker</td>
<td>689</td>
</tr>
<tr>
<td>Transplant Aspiration Cytology Detects Entities Other Than Acute Cellular Rejection in Liver Allografts</td>
<td>C.L. Greene, I. Fehrman, G.W. Tillery, B.S. Husberg, and G.B. Klintmalm</td>
<td>692</td>
</tr>
<tr>
<td>Polymorphic HLA-A and HLA-B Antigens Are Induced in Rejecting Liver Grafts</td>
<td>G. Steinhoff, K. Wonigeit, and R. Pichlmayr</td>
<td>698</td>
</tr>
</tbody>
</table>

**EXPERIMENTAL STUDIES**

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum Ionized Calcium (Ca$^{+2}$) After Calcium Gluconate Administration in Anhepatic Patients During Orthotopic Liver Transplantation</td>
<td>K.M. Robertson, J.M. Marquez, Jr, T.A. Gasior, and F. Fortunato</td>
<td>701</td>
</tr>
</tbody>
</table>

(Continued)
CONTENTS
(continued)


Expression of HLA Antigens on Hepatocytes in Liver Disease .......... S.N. Thung, F. Schaffner, and M.A. Gerber 722

Role of HLA in Intragraft Cellular Immunity in Human Liver Transplantation R.J. Duquesnoy, S. Saidman, B.H. Markus, A.J. Demetris, and A. Zeevi 724

Establishment of Primary Cultures of Human Biliary Epithelium and Induction of Class II Major Histocompatibility Complex Antigens by Interferon Gamma A.J. Demetris, B. Markus, S. Saidman, J. Fung, L. Makowka, R. Duquesnoy, and T.E. Starzl 728

Prolonged Survival of Hepatic Xenografts in the Hamster to Rat Combination: Efficacy of Cyclosporine in Combination With Splenectomy .......... Y. Yamaguchi, R. Harland, and R.R. Bollinger 731

HEART AND HEART-LUNG TRANSPLANTATION

CLINICAL ASPECTS

Heart Transplantation at the University of Pittsburgh: 1980 to 1987 ...... R.L. Hardesty 737

Immunologic and Blood Group Compatibility in Cardiac Transplantation R.L. Kormos, Y.L. Colson, R.L. Hardesty, B.P. Griffith, A. Trento, M. Vanek, R.J. Duquesnoy, and A. Zeevi 741

Late Follow-Up of Children After Heart Transplantation ............. E. Pahl, F.J. Fricker, A. Trento, B. Griffith, R. Hardesty, L. Gold, K. Lawrence, L. Beerman, D. Fischer, and W. Neches 743

(Continued)
CONTENTS
(continued)

The Role of Surveillance Bronchoscopy and Bronchoalveolar Lavage Prior to Heart Transplantation........................M. Stahl, A. Moulton, T. Sears, J. Linder, S.E. Marriott, and S. Rennard 747


Prolonged Amrinone Therapy Prior to Orthotopic Cardiac Transplantation in Patients With Pulmonary Hypertension...........S.F. Bolling, G.M. Deeb, D.C. Crowley, M.M. Badellino, and E.L. Bove 753

Resting Hemodynamics After Heart Transplantation: Insensitive Markers for Occurrence or Severity of Cardiac Rejection........M. Badellino, N.C. Cavarocchi, J. Kolff, J.B. McClurken, and M. Jessup 757


Histopathology of Transbronchial Biopsies in Heart-Lung Transplantation
S. Stewart, T.W. Higenbottam, J.A. Hutter, A.R.L. Penketh, T.J. Zebro, and J. Wallwork 764

Transbronchial Lung Biopsy to Diagnose Lung Rejection and Infection of Heart-Lung Transplants............................ T. Higenbottam, S. Stewart, and J. Wallwork 767

Cytoimmunologic Monitoring in Heart Transplant Patients....................G. Ippoliti, A. Gavazzi, G. Bajani, B. Rovati, C. Campana, D. Arrigoni, L. Martinelli, G. Minzioni, A. Graffigna, and M. Vigano 770


Is In-111 Antimyosin Antibody a Useful Diagnostic Marker for Evaluation of Early Cardiac Allograft Rejection?..........K. Ueda, K. Takeda, N.D. LaFrance, K. Solez, W.A. Baumgartner, B.A. Reitz, and A. Herskowitz 778

Patient Selection and Results of Cardiac Transplantation in Patients With Cardiomyopathy...... M.E. Thompson, R.L. Kormos, A. Zerbe, and R.L. Hardesty 782

(Continued)
CONTENTS
(continued)

Congenital Cardiac Malformation With Left-to-Right Shunt and Evolutive Pulmonary Hypertension: An Indication for Isolated Orthotopic Heart Transplantation


Azathioprine to Reverse Renal Dysfunction After Heart Transplantation M. Schneider, N.C. Cavarocchi, M. Jessup, J.B. McClurken, J. Dunn, B. Narins, R. Balsara, C. Viewig, and J. Kolff 795

Heterotopic Cardiac Transplantation ....................... W.F. Konertz, M. Weyand, A. Friedl, and A. Bernhard 798

On the Usefulness of Lithium Carbonate Administration for Immunosuppressive Drug-Induced Leukopenia in Heart Transplant Patients ......................... G. Ippoliti, A. Gavazzi, C. Campana, L. Martinelli, G. Minzioni, E. Ascari, M. Vigano, and R. Rondanelli 799

Antihypertensive Therapy in Patients After Cardiac Transplantation: A Step-Care Approach ........ M. Jessup, N. Cavarocchi, B. Narins, J. McClurken, and J. Kolff 801

The Physiological Management of Cardiac Transplant Donors and Recipients Using Triiodothyronine .............................. D. Novitzky, D.K.C. Cooper, and N. Zuhdi 803

The Neuropathology of Liver, Heart, and Heart-Lung Transplantation A.J. Martinez and J. Puglia 806


(Continued)
EXPERIMENTAL


Pressure Volume Relationships as a Determinant of Myocardial Ventricular Function in an Autoperfusing Heart-Lung Preparation........ M.M. Badellino, G.M. Deeb, J. Horowitz, M. Adesman, B. Dennenberg, J. White, and J. Kolff 820


Orthotopic Transplantation of Resuscitated Canine Heart-Lung Units ........... S.J. Dos and I. Erdamar 826

Dynamics of Bronchoalveolar Lavage in the Canine Lung Transplant.......... D. Herlan, R. Kormos, A. Zeevi, I. Paradis, L. Wei, M. Nalesnik, R. Hardesty, and B. Griffith 832


Antibody Titers and Cardiac Allograft Survival in the Sensitized Rat Model: Effect of Time After Initial Sensitization....... R.C. Harland, S.J. Knechtle, Y. Yamaguchi, and R.R. Bollinger 839


Hyperacute Rejection After Portacaval Shunt in the Rat ......................... G. Mazzoni and P. Mazzoni 844


PANCREAS TRANSPLANTATION

CLINICAL STUDIES

Pancreas Transplantation—The Minnesota Experience........ J.S. Najarian, F.C. Goetz, and D.E.R. Sutherland 859

(Continued)
CONTENTS
(continued)

Pancreatic Transplantation for Diabetes Mellitus: The Stockholm Experience
C.G. Groth, G. Tydén, C. Brattström, S-O. Bohman, and J. Östman 862

Improving Patient and Graft Survival Rates in Pancreatic Transplantation
J.L. Smith, F.H. Wright, B. Schanbacher, and R.J. Corry 866

Prevention, Stabilization, and Reversal of the Metabolic Disorders and Secondary
Complications of Diabetes by Pancreas Transplantation....................... M.J. Orloff,
A. Macedo, C. Macedo, N. Yamanaka, Y-T. Huang, D-G. Huang, X-S. Leng,
A. Stieber, I. Kreidieh, and G. Greenleaf 868

Course of Diabetic Microangiopathy After Simultaneous Pancreas and Kidney
Transplantation..................D. Abendroth, R. Landgraf, W-D. Illner, and W. Land 874

Clinical Pancreaticoduodenal Allotransplantation With Inclusion of the Donor Spleen
(Irradiated and Nonirradiated) to Prevent Thrombosis.........................D.C. Dafoe,
L. Rosenberg, D.A. Campbell, Jr, R.M. Merion, A.S. Lichter,
and J.G. Turcotte 876

Evolution of Synchronous Renal and Segmental Pancreatic Transplantation Into a
Therapeutic Modality ................M.A. Castaneda, P.J. Garvin, K. Carney, J. Hoff,
and D. Aridge 878

Plasma Fluoride Concentration After Isoflurane Anesthesia in Patients Subjected to
Combined Renal and Pancreatic Transplantation........... L. Eleborg, B.I. Blomqvist,
G. Tydén, and C-J. Spak 881

Correlation of Levels of Urinary Insulin With Pancreatic Allograft Dysfunction in
Bladder-Drained Experimental and Clinical Pancreas Transplants
F.T. Thomas, W.T. Bogey, W. Castellani, P. Khazanie, C. Viola, D. Stelzer,
C. Sash, and J. Thomas 884

Intra-Abdominal Fluid Collections in Pancreas Transplant Recipients: Bladder Versus
Enteric Drainage...................... G.W. Burke, D.E.R. Sutherland, and J.S. Najarian 887

Improved Results of Pancreatic Transplantation With the Delayed Duct Occlusion
Technique ....................... R. Margreiter, A. Königsrainer, E. Steiner, T. Schmid,
and H. Pernthaler 889

PANCREATIC ISLET
TRANSPLANTATION

Multiple-Donor Composite and Sequential Allografts: A New Approach to Pancreatic
Islet Transplantation... T. Kanai, M. Gotoh, J. Porter, A.P. Monaco, and T. Maki 891

Microbial Contamination Risks in Human Islet Isolation...................... M.P. Corlett,
D.W. Scharp, and P.E. Lacy 894

(Continued)
CONTENTS
(continued)
Long-Term Normoglycemia in Canine Islet Autografts.......M.P. Corlett, D. Alderson, N.M. Kneteman, and D.W. Scharp 896

EXPERIMENTAL

Urinary pH for Pancreas Allograft Function...............H.K. Oh, K.L. McCullough, F.S. Shamash, and N.A.Turza 898


The Importance of the Right Pancreas Lobe in Enteroinisular Axis Operation
M. Gotoh, M. Monden, Y. Motoki, J. Okamura, T. Mori, and K. Shima 904

Irradiation to Reduce Exocrine Secretion in Porcine Segmental Pancreas Transplantation............R.K. Thompson, C.T. Lum, J.R. Davis, and C.E. Knabel 906


The Use of Antiplatelet Agents on Canine Whole Organ Pancreas Allografts
H.K. Oh, F.S. Shamash, S.G. Dienst, and M.W. Lee 910

TRANSPLANTATION OF OTHER ORGANS

Experimental Small Bowel Transplantation ...........S. Raju, R. Shimazu, H. Fujiwara, J.B. Grogan, J.L. Achord, and J.R. Lewin 915

Homotransplantation of Testis: Experimental Study and Clinical Practice
(13 Case Reports) ..............B. Zhan, L. Wang, X. Zhang, Y. Sun, and M. Chen 918

ORGAN PROCUREMENT AND PRESERVATION

BASIC PRINCIPLES

Principles of Organ Preservation..............................................................F.O. Belzer 925

(Continued)
## CONTENTS (continued)

The Development of an Organ Donation Protocol From the Perspective of the Donor Family and Donor Hospital.........................J.A. O'Connor, M. Kivell, R.H. Riddel, and J. Venturelli 928

### KIDNEY


Cadaver Kidney Transplantation With Prolonged Cold Ischemia Time........M. Haberal, H. Gulay, G. Arslan, and N. Bilgin 932

Successful 72-Hour Cold Storage Kidney Preservation With UW Solution


### LIVER


Twenty-Four-Hour Liver Preservation Using Artificial Blood Substitutes

I. Nakajima, S. Fuchinoue, S. Teraoka, T. Kawai, H. Honda, T. Agishi, and K. Ota 942

Successful 24 to 30-Hour Preservation of the Canine Liver: A Preliminary Report

N.V. Jamieson, R. Sundberg, S. Lindell, R. Laravuso, M. Kalayoglu, J.H. Southard, and F.O. Belzer 945


Energy Metabolism in Warm Ischemically Damaged Liver Grafts After Transplantation and Protection by Coenzyme Q$_{10}$ Pretreatment.......K. Sumimoto, K. Inagaki, S. Marubayashi, T. Kawasaki, and K. Dohi 958

(Continued)
### CONTENTS
(continued)

Superoxide Dismutase Improves Organ Preservation in Liver Transplantation  
*L.M. Olson, G.B. Klintmalm, B.S. Husberg, J.R. Nery, C.W. Whitten,  
A.W. Paulsen, and R. McClure*  
*961*

Amelioration of Normothermic Canine Liver Ischemia With Prostacycl...  
*S. Todo,  
H. Yokoi, L. Podesta, P. ChapChap, C. Pan, K. Okuda, Y. Kamiyama,  
J. Demetris, L. Makowka, S. Iwatsuki, and T.E. Starzl*  
*965*

Fluorometric Study for the Noninvasive Determination of Cellular Viability in  
Perfused Rat Livers.....  
*R. Okamoto, Y. Tokunaga, N. Ozaki, T. Kiuchi, Y. Sakai,  
R. Okamura, H. Utsunomiya, M. Ukikusa, K. Tanaka, Y. Yamaoka, K. Ozawa,  
and Y. Nakase*  
*969*

The Protective Effect of SRI 63-441 on Ischemic Liver Injury Using the Isolated  
Perfused Rat Liver: Combined Protocol With Superoxide Dismutase  
*S.J. Ontell, L. Makowka, V. Mazzaferro, J. Trager, P. Ove, and T.E. Starzl*  
*972*

Role of Free Radicals in Ischemic Rat Liver Preservation: Prevention of Damage by  
Vitamin E, CoQ10, or Reduced Glutathione Administration ..........  
*S. Marubayashi,  
K. Dohi, K. Sumimoto, K. Sugino, K. Ochi, and T. Kawasaki*  
*974*

Development of an Ectopic Liver by Transplantation of Cryopreserved Hepatocytes  
*P. Maganto, J.A. Cienfuegos, L. Santamaria, G. Eroles, J.L. Castillo-Olivares,  
and A.M. Municio*  
*976*

### HEART AND HEART-LUNG

The Influence of Donor Organ Stability and Ischemia Time on Subsequent Cardiac  
Recipient Survival .............  
*R.L. Kormos, W. Donato, R.L. Hardesty, B.P. Griffith,  
J. Kiernan, and A. Trento*  
*980*

Eurocollins Solution for Heart Preservation: Experimental and Clinical Experience  
*W.F. Konertz, B. Saka, and A. Bernhard*  
*984*

Evaluation of Current Organ Preservation Methods for Heart-Lung Transplantation  
*C.D. Fraser, Jr, F. Tamura, G.J. Kontos, Jr, H. Adachi, K. Campbell,  
G.M. Hutchins, A.M. Borkon, B.A. Reitz, and W.A. Baumgartner*  
*987*

The Autoperfusing Pressure-Stabilized Heart-Lung Preparation: Hemodynamic  
Function After 20 Hours of Perfusion ...  
*F. Robicsek, G.D. Duncan, T.N. Masters,  
H.E. Rice, G. Kertesz, M.H. Denyer, and W.F. Poveromo*  
*991*

### PANCREAS

Combined Liver and Pancreas Harvesting From Cadaveric Donors ..........  
*J.L. Faure,  
P.H. Takvorian, P. Champetier, J. Neidecker, R. Landraud, L. Camozzi,  
and R. Sanseverino*  
*994*

(Continued)
CONTENTS
(continued)
Prolongation of Islet Xenograft Survival by Islet Irradiation and Antilymphocyte Serum Treatment of Recipients...M. Gotoh, J. Porter, A.P. Monaco, and T. Maki 997

PUBLIC ASPECTS OF TRANSPLANTATION

ORGAN PROCUREMENT

<table>
<thead>
<tr>
<th>Title</th>
<th>Author</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organ Procurement in Western Europe</td>
<td>C. Wight</td>
<td>1003</td>
</tr>
<tr>
<td>Organ Procurement</td>
<td>P.D. Taylor</td>
<td>1007</td>
</tr>
<tr>
<td>Organ Procurement: Fulfilling a Need</td>
<td>B.A. Broznick</td>
<td>1010</td>
</tr>
</tbody>
</table>

ORGAN ALLOCATION

<table>
<thead>
<tr>
<th>Title</th>
<th>Author</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Policy and Organ Distribution</td>
<td>R.J. Corry</td>
<td>1011</td>
</tr>
<tr>
<td>A National Allocation System</td>
<td>R. Mendez</td>
<td>1014</td>
</tr>
<tr>
<td>Tissue Transplantation: Allocation and Related Issues</td>
<td>G.E. Friedlaender</td>
<td>1017</td>
</tr>
<tr>
<td>Organ Allocation: How Can We Assure Equitable Distribution?</td>
<td>P.S. Russell</td>
<td>1022</td>
</tr>
<tr>
<td>Getting Organ. . .ized</td>
<td>B. Schulman</td>
<td>1025</td>
</tr>
<tr>
<td>Allocation of Cadaver Kidneys for Transplantation</td>
<td>G. Opelz</td>
<td>1028</td>
</tr>
</tbody>
</table>

PUBLIC INFORMATION

<table>
<thead>
<tr>
<th>Title</th>
<th>Author</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panel on Public Information</td>
<td>C.C. Sprague</td>
<td>1033</td>
</tr>
<tr>
<td>Public Information and Transplantation From a Recipient's Point of View: The Case for Donor Confidentiality</td>
<td>J.C. Pennington</td>
<td>1036</td>
</tr>
<tr>
<td>The Media and the Transplant Issue: Why They Do What They Do</td>
<td>J. Greenfield</td>
<td>1038</td>
</tr>
</tbody>
</table>

HEALTH CARE FINANCING IN TRANSPLANTATION

<table>
<thead>
<tr>
<th>Title</th>
<th>Author</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Who Pays for Organ Transplantation?</td>
<td>J.R. Mande</td>
<td>1041</td>
</tr>
<tr>
<td>Organ Transplant Coverage and Reimbursement</td>
<td>S. Gleeson</td>
<td>1044</td>
</tr>
<tr>
<td>Federal Financing of Transplantation</td>
<td>C.R. Anthony</td>
<td>1047</td>
</tr>
</tbody>
</table>

(Continued)
CULTURAL, ETHICAL, AND RELIGIOUS ASPECTS OF TRANSPLANTATION

ETHICAL CONSIDERATIONS

Ethical Issues in Organ Allocation ................................................................. J.B. Dossetor 1053
Approach to the Ethics of Transplantation ...................................................... R. Smith 1059
Three Ethical Revolutions: Ancient Assumptions Remodeled Under Pressure of Transplantation ................................................................. F.D. Moore 1061
Live Renal Donation: A Viewpoint ................................................................. C.T. Patel 1068

RELIGIOUS AND CULTURAL ISSUES

Organ Transplantation, Medical Ethics, and Jewish Law .................................... D.W. Weiss 1071
The Buddhist View of the Body and Organ Transplantation .............................. K.T. Tsuji 1076
Religious Obstacles and Warrants for the Donation of Body Parts ..................... W.F. May 1079
Islamic Views on Organ Transplantation ....................................................... A.A. Sachedina 1084

LIFE AFTER TRANSPLANTATION

Introduction ......................................................................................................... E. Zechman 1091
Life After Transplantation ................................................................................ L. Gutkind 1092

NOTICE

Dr S.E. Skanes of The Royal Victoria Hospital, Montreal, Canada, wishes to inform the readership that the correct authorship of the article “Tissue Transplantation for Reconstructive Surgery,” which appeared in TRANSPLANTATION PROCEEDINGS, 1986, Volume 18:898-900 is: S.E. Skanes, D.D. Samulack, R.D. Daniel, and E.P. Egerszegi.
Quadruple-Drug Induction Therapy in Highly Sensitized Patients

W-D. Miner, S. Schleibner, D. Abendroth, and W. Land

The immunologic prognosis of a renal allograft correlates—at least in part—with the state of preformed cytotoxic antibodies of the recipient. Patients with reactivity against more than 50% of the test panel had an inferior graft outcome compared with patients with fewer or no antibodies. To demonstrate a beneficial effect of quadruple-drug induction therapy in highly sensitized patients we treated 40 presensitized recipients with an immunosuppressive protocol consisting of low-dose cyclosporine (CyA), azathioprine, antilymphocyte/antithymocyte globulin (ALG/ATG), and high-dose steroids for a short period of time. In this study we expected a reduced nephrotoxic side effect of CyA, a satisfied immunosuppressive index, and an acceptable complication rate. Parts of this study have already been published elsewhere.

Patients and Methods

From August 1985 to August 1987 we performed 40 cadaveric kidney transplantations in highly sensitized patients. The latest mean level of preformed lymphocytotoxic antibodies was 65% (minimum, 30%; maximum, 98%). Seventeen of these patients received a first graft, 17 patients received a second transplant, four patients received a third graft, and two patients received a fourth transplant. Most of the recipients received a well-matched graft. The mean mismatch at the HLA-A locus was 1.1; at the HLA-B locus, 1.2; and at the HLA-DR locus, 0.6.

The immunosuppressive protocol (induction phase) consisted of CyA starting at 6 mg/kg body weight orally, and later increased to achieve whole blood target CyA trough levels between 300 and 500 ng/mL, azathioprine at 1 to 2 mg/kg body weight for 3 weeks, ATG/ALG at 4 mg/kg body weight for seven days, and methylprednisolone at 500 mg/d tapered to 30 mg/d within 1 week.

Results

The 2-year graft survival probability (Cutler/Ederer formula) in this study group is 72% (Fig 1). No patient died during the follow-up period from August 1985 to August 1987. The infection rate of 15% is low. The myelodepressive effect in 22% was reversed in all patients after withdrawing azathioprine therapy. Acute nephrotoxicity was observed in only three patients.

Conclusion

Quadruple-drug induction therapy improves kidney graft survival in highly sensitized patients. This immunosuppressive protocol is a safe approach because the infectious complications are low and the early nephrotoxic side effect of CyA is greatly reduced. The frequency of rejection episodes (55%) is increased, and this is the point of great interest—most of them are associated with CyA trough values smaller than 200 ng/mL within 2 weeks posttransplant (Fig 2). The reversal

From the Division of Transplant Surgery, Department of Surgery, Klinikum Grosshadern, University of Munich.

Address reprint requests to W.-D. Illner, MD, Division of Transplantation Surgery, Klinikum Grosshadern, Marchioninistr 15, 8000 Munich 70, FRG.

© 1988 by Grune & Stratton, Inc.
0041-1345/88/2001-1153$03.00/0

Fig 1. Survival in highly sensitized patients. Two-year graft survival probability (Cutler/Ederer formula) in this study group from August 1985 to August 1987. ▲ , Graft survival; —, patient survival.
under antirejection treatment might suggest that the starting dose of CyA (6 mg/kg body weight orally) was not sufficient and should be corrected to get CyA trough levels above this value, at least in this category of patients.

REFERENCES
1. Iwaki Y, Terasaki PI: Clin Transplant 257, 1986
2. Opelz G: Prog Allergy 38:329, 1986